Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
information fournie par Boursorama CP 06/06/2022 à 08:00
Ajoutez Boursorama à vos sources préférées

Strasbourg, France, June 6, 2022, 8:00 am CEST - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that it presented updated preliminary Phase I data on TG4050, its individualized neoantigen cancer vaccine, in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting. TG4050 is based on Transgene’s myvac® platform and powered by NEC’s cutting-edge AI capabilities.

These additional positive initial data, including molecular (ctDNA) response, have been generated from the first patients with ovarian cancer and HPV-negative head and neck cancer enrolled in the two ongoing Phase I trials assessing TG4050. They were presented in-person in Chicago, IL, June 5, 2022.

.../...

Valeurs associées

TRANSGENE
0,8080 EUR Euronext Paris -3,58%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
93,7 +0,49%
Or
4 608,19 0,00%
CAC 40
8 484,43 +0,37%
EUR/USD SPOT
1,16765 0,00%
2CRSI
26,64 +3,34%
Chargement...

Pages les plus populaires

L'offre BoursoBank